ArticleBritish journal of cancer2013

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

R D Harvey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.